Central Hospital Saint Quentin Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2016
NCT02902731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Central Hospital Saint Quentin

Active Ingredients

Drugs in Phase 3 Trials (1)

anakinra (kineret) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteritis (Phase 3)

Giant Cell Arteritis (Phase 3)

Polymyalgia Rheumatica (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1